Company intelligence / Profile preview

Loba biotech

Fischamend, Lower Austria, Austrialobabiotech.com ↗

Ownership: Private
Employees: ~100
Development stage: Other

Overview

Loba biotech has established a state-of-the-art GMP biopharmaceutical center near Vienna, Austria, focused on the production of high-quality active pharmaceutical ingredients. The company’s lead product is peginterferon alfa‑2a (Pegasys®), with commercial supply targeted for 2025. The facility supports both clinical and commercial manufacturing, emphasizing sustainability and regulatory compliance.

Therapeutic areas: HematologyOncologyInfectious Diseases
Modalities: ProteinPegylated protein (peginterferon alfa-2a)
Industry: Contract Manufacturing Organization

Partnerships

VTU Group (engineering/technical consultancy during facility construction)

Beyond the preview

Go deeper on Loba biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Loba biotech.

Explore the full profile